For the treatment of hyperadrenocorticism (Cushing's disease) in dogs
For treatment of some types of cancer affecting the adrenal cortex What dogs / cats should not take this medication?
One of the
first treatments of this type, developed as early as 2004, specifically aims at slowing the growth of new blood vessels and at preventing neovascularisation of tumours.
Better testing is needed because recent changes in who gets each form of the disease have made it risky to categorize patients based on their age, ethnicity or weight, as was common in the past, and also because of growing evidence that early,
aggressive treatment of type - 1 diabetes improves patients» long - term prognoses.
Parvus Therapeutics is focused on the development and commercialization of the nanotechnology - based therapeutic platform for the
potential treatment of type 1 diabetes.
The mission of ACGT is to support the extraordinary potential offered by cell and gene - based therapies to accelerate effective and
safe treatment of all types of cancer.
It was approved by the FDA for
diabetes treatment of type 2 diabetes in 1994 (not type 1, which is the result of an autoimmune disorder) though it was available in other countries before then.
Two case studies provide an important potential new avenue
for treatment of these types of tumors, which are resistant to traditional radiation therapies and difficult to manage even with surgery, the current standard of care.
For heartworm prevention in dogs and cats For treatment and control of adult and immature hookworm infections in cats For
treatment of some types of mange Topical solution is used to treat ear mites What dogs / cats should not take this medication?
Brown rice, for example, is a rich source of ferulic acid, which is being explored for a variety of health benefits ranging from anti-aging and cancer prevention to
the treatment of type 2 diabetes.
Ophthalmology (New England Eye Center) at Floating Hospital for Children at Tufts Medical Center specializes in the testing and
treatment of all types of eye diseases and visual problems.
«Antibody holds promise for
treatment of Type 1 diabetes.»
Yissum, the technology transfer company of the Hebrew University, together with partners, signed an exclusive license agreement with BioLineRx to develop and commercialize BL - 9020 for
the treatment of Type 1 diabetes.
It is possible that medical advances over the past few decades in
the treatment of type 2 diabetes, hypertension and high cholesterol levels have had a greater impact on people who are overweight — which increases the risk for these conditions — whereas the effect was much smaller in those of normal weight.
«This is the first license - enabling trial of a cellular product for
treatment of type 1 diabetes,» said NIAID Transplantation Branch Chief Nancy D. Bridges, M.D., a co-author of the paper.
This really is a game changer in
the treatment of type 2 diabetes.
The study by The George Institute for Global Health has major implications for
the treatment of type 2 diabetes which affects around 450 million people worldwide.
Dr. Dong said the findings have significant implications in the prevention and
treatment of type 2 diabetes and could prove to be useful targets for modulation of insulin sensitivity and glucose homeostasis and as a target for therapeutic agents to increase liver function to prevent diabetes.
«This gene needs to be there, and should be considered a target to consider in
the treatment of type 2 diabetes and / or obesity.»
Knowing that inflammation improves insulin signaling rather than hindering it could usher in a new era for
treatment of type 2 diabetes, one that targets molecules in the inflammatory pathway.
Liraglutide is manufactured and licenced by Novo Nordisk and is currently licenced for
the treatment of Type II diabetes.
New research published in The Lancet has shown that a drug, currently used in
the treatment of Type II diabetes, can be effective in clearing fatty liver disease from some patients.
«This is the first randomized controlled trial demonstrating that
treatment of type 2 diabetes in overweight people by substantial weight loss is safe and hugely beneficial,» Professor O'Brien said.
Gastric banding can play a vital role in
the treatment of type 2 diabetes in people who are overweight and not obese, according to new research.
The paper provided the latest results from the SLIMM - T2D (Surgery or Lifestyle with Intensive Medical Management in
the Treatment of Type 2 Diabetes) study, which randomly allocated 38 obese patients with type 2 diabetes to treatment either by surgery at BWH or through an intensive lifestyle management program at Joslin.
«Potential cost savings for early detection and
treatment of type 2 diabetes.»
Dr. Kulkarni's research focuses on investigating signaling pathways impacting growth and function of pancreatic islet cells with the long - term goal of improving therapeutic approaches for
the treatment of type 1 and type 2 diabetes and obesity - associated conditions.
This study reveals activators of mitochondrial protein Mitofusin 2 that may be valuable in
the treatment of type 2 diabetes.
Known as SLIMM - T2D (Surgery or Lifestyle with Intensive Medical Management in
the Treatment of Type 2 Diabetes), the two - year study will examine whether patients test in the non-diabetic range one year after either the surgical or medical and weight management interventions.
A team headed by Antonio Zorzano at IRB Barcelona has identified activators of the mitochondrial protein Mitofusin 2 for
the treatment of type 2 diabetes.
Dr. Laikind will review recent progress with the company's VC - 01 ™ islet replacement product candidate for
the treatment of type 1 diabetes, which recently entered the clinical phase of development.
The company is also developing novel strategies for the prevention and
treatment of Type II diabetes.
We have made the difficult decision to pause enrollment for our study of LMI070 for
the treatment of Type 1 Spinal Muscular Atrophy (SMA).
New research in SCTM describes a safe and effective new strategy for
the treatment of type 1 diabetes using induced pluripotent stem cell - derived progenitors
ViaCyte's PEC - EncapTM (also known as VC - 01TM) product candidate is the first pluripotent stem cell - derived islet cell replacement therapy for
the treatment of type 1 diabetes in clinical - stage development.
Providing data and tools to promote understanding and
treatment of type 2 diabetes and its complications
Dr. Brandon will review recent progress with the company's VC - 01 ™ product candidate for
the treatment of type 1 diabetes, which recently entered the clinical phase of development.